NEWS CENTER

PRESS RELEASES

09.09.2019
Epic Sciences Expands Executive Leadership Team - Appoints Joel Smith as General Counsel and Executive Vice President of Corporate Development
Epic Sciences today announced the appointment of Joel Smith as its general counsel and executive vice president of corporate development. Mr. Smith joins the company’s impressive roster of industry veterans. Read Full Release
05.30.2019
Published Study Demonstrates Feasibility of a Blood Test to Predict Disease Progression and Metastasis in Localized Prostate Cancer
Epic Sciences announced the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic’s CTC technology platform, is published in the Journal of Clinical Oncology Precision Oncology. Read Full Release
05.22.2019
Epic Sciences Appoints New Chief Technology Officer
Epic Sciences announced that it has named Chockalingam “Palani” Palaniappan as its new chief technology officer to help the company advance its Functional Cell Profiling technology to drive global expansion. Read Full Release
05.15.2019
Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019
Epic Sciences, Inc. today announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois. Read Full Release

NEWS

07.01.2019 | Genetic Engineering & Biotechnology News
Liquid Biopsy Technologies Diversify in Expanding CTC Field
The field of circulating tumor cells (CTCs) is exploding with competing technologies, all offering different approaches to isolating and characterizing CTCs from blood. CTCs are incredibly rare. Out of ten billion blood cells, only a handful may be CTCs. They are believed to be the mechanism behind cancer metastasis, and there is a great deal of interest in using them to diagnose, monitor, and predict the course of the disease. Read Full Article
04.05.2019 | COMPELO
Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial
Epic Sciences and its research partners report the use of the company's new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930). Read Full Article
03.27.2019 | The Pathologist
A Fluid Future - Why are there inconsistencies between different liquid biopsy tests – and how can the field evolve to maximize accuracy and impact?
Advances in disease profiling over recent years have opened new doors in the quest for early diagnosis and personalized treatment, with metastatic prostate cancer being a case in point. As the most widespread malignancy affecting men in the USA – 174,650 new cases and 31,620 deaths are predicted for 2019 – prostate cancer research is crucial. One such breakthrough is the use of liquid biopsy tests to detect circulating tumor DNA (ctDNA) in patients’ blood, offering a minimally invasive method of disease profiling. Read Full Article
03.25.2019 | FierceBiotech
Epic Sciences nets Myriad’s cancer president to serve as its CEO
Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO. Sanders takes over for Murali Prahalad—who is stepping down after six years to pursue new opportunities, according to the company—though Prahalad will maintain a seat on Epic’s board of directors. Read Full Article

EVENTS

SABCS 2019
The Epic Sciences team will be attending and exhibiting at the San Antonio Breast Cancer Symposium - Booth #626 - in San Antonio, TX from December 10 - December 14, 2019. More Info
ASCO 2019
The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019. More Info
AACR 2019
The Epic Sciences team attended AACR Annual Meeting - Booth #4455 - in Atlanta, GA from March 29 - April 3, 2019. More Info
ASCO GU 2019
The Epic Sciences team attended the ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019. More Info